ArticleScientific reports2025
Comprehensive exploration of programmed cell death landscape in lung adenocarcinoma combining multi-omic analysis and experimental verification.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Regulated cell death plasticity in cancer: thresholds, reversibility, and therapeutic failure.Journal of translational medicine · 2026Review
- Prognostic and immunotherapeutic implications of histamine-related biomarkers in lung adenocarcinoma.PeerJ · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mortality and therapeutic failure in lung adenocarcinoma (LUAD) are mainly resulted from the wide metastasis and chemotherapy resistance. Up to now, accurate and stable predictive prognostic indicator for revealing the progress and novel therapeutic strategies of LUAD is infrequent, nonetheless. Diversified programmed cell death (PCD) has been widely confirmed that participated in the occurrence and development of various malignant tumors, respectively. In this research, we integrated fourteen types of PCD, bulk multi-omic data from TCGA-LUAD and other cohorts in gene expression omnibus (GEO) and clinical LUAD patients to develop our analysis. Consequently, pivotal fourteen PCD genes, especially CAMP, CDK5R1, CTSW, DAPK2, GAB2, GAPDH, GATA2, HGF, MAPT, NAPSA, NUPR1, PIK3CG, PLA2G3, and SLC7A11, were utilized to establish the prognostic signature, namely cell death index (CDI). The validation in several external cohorts indicated that CDI can be regarded as a potential risk factor of LUAD patients. Combined with other common clinical information, a nomogram with potential predictive ability was constructed. Besides, according to the CDI signature, the tumor microenvironment (TME) and sensitivity to some potential chemotherapeutic drugs were further and deeply explored. Notably, verification and functional experiments further demonstrated the remarkable correlation between CDI and unfold protein response. Given all the above, a novel CDI gene signature was indicated to predict the prognosis and exploit precision therapeutic strategies of LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.